EUCTR2017-001772-28-SE进行中（未招募）1 期
An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib in Patients with Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis Previously Treated with Ruxolitinib
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 150
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. PMF, PPV-MF, or PET-MF (as defined by Tefferi and Vardiman 2008, Appendix 4)
- •2. DIPSS Intermediate-1, Intermediate -2, or High risk (Passamonti et al. 2010, Appendix 3)
- •3. Prior ruxolitinib treatment with failure to benefit or intolerance as defined by at least one of the following:
- •a. Treatment for =3 months with inadequate efficacy response defined as <10% spleen volume reduction by MRI or <30% decrease from baseline in spleen length by physical examination or regrowth to to these parameters following an initial response; and/or
- •b. Treatment for =28 days complicated by either:
- •i. Development of a red blood cell transfusion requirement (at least 2 units/month for 2 months)
- •ii. NCI CTCAE grade =3 AEs of thrombocytopenia, anemia, hematoma, and/or hemorrhage while being treated with a dosage of <20 mg BID
- •4. Palpable splenomegaly =5 cm below the lower costal margin (LCM) in the midclavicular line as assessed by physical examination
- •5. TSS of =10 on the MPN-SAF TSS 2.0 or patients with a single symptom score of =5 or two symptoms =3 including only the symptoms of left upper quadrant pain, bone pain, itching or night sweats (Appendix 3)
- •6. Age =18 years old
- •7. Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2 (Appendix 6)
- •8. Peripheral blast count of <10% throughout the screening period
- •9. Absolute neutrophil count of >500/µL
- •10. Adequate liver and renal function, defined by liver transaminases (aspartate aminotransferase [AST]/serum glutamic oxaloacetic transaminase [SGOT] and alanine aminotransferase [ALT]/serum glutamic pyruvic transaminase [SGPT]), =3 × the upper limit of normal (ULN) (AST/ALT =5 × ULN if transaminase elevation is related to MF), direct bilirubin =4× ULN, and creatinine =2.5 mg/dL
- •11. Adequate coagulation function, defined by prothrombin time (PT)/international normalized ratio (INR), partial thromboplastin time (PTT), or thrombin time (TT) of =1.5 × ULN
- •12. Left ventricular cardiac ejection fraction (LVEF) of =45% by echocardiogram or multigated acquisition (MUGA) scan
- •13. If fertile, willing to use effective birth control methods during the study
- •14. Willing to undergo and able to tolerate frequent MRI or CT assessments during the study
- •15. Able to understand and willing to complete symptom assessments using a patient-reported outcomes instrument
- •16. Provision of informed consent
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 60
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 90
排除标准
- •1. Life expectancy <6 months
- •2. Completed allo-SCT or are eligible for and willing to complete allo-SCT
- •3. History of splenectomy or planning to undergo splenectomy
- •4. Splenic irradiation within the last 6 months
- •5. Previously treated with pacritinib
- •6. Patients receiving high-dose ruxolitinib (more than 10 mg BID or 20 mg QD) who cannot tolerate tapering down ruxolitinib to 10 mg BID or less prior to the first dose of pacritinib
- •7. Treatment with anticoagulation or antiplatelet agents, except for aspirin dosages of =100 mg per day, within the last 2 weeks
- •8. Treatment with a strong CYP3A4 inhibitor or a strong cytochrome P450 inducer within the last 2 weeks
- •9. Treatment with medications that can prolong the QTc interval within the last 2 weeks
- •10. Treatment with an experimental therapy within the last 28 days
- •11. Significant recent bleeding history defined as NCI CTCAE grade =2 within the last 3 months, unless precipitated by an inciting event (e.g., surgery, trauma, injury)
- •12. Any history of CTCAE grade =2 non-dysrhythmia cardiac conditions within the last 6 months. Patients with asymptomatic grade 2 non-dysrhythmia cardiac conditions may be considered for inclusion, with the approval of the medical monitor, if stable and unlikely to affect patient safety.
- •13. New York Heart Association Class II, III, or IV congestive heart failure
- •14. Any history of CTCAE grade =2 cardiac dysrhythmias within the last 6 months. Patients with non-QTc CTCAE grade 2 cardiac dysrhythmias may be considered for inclusion, with the approval of the medical monitor, if the dysrhythmias are stable, asymptomatic, and unlikely to affect patient safety.
- •15. QTc prolongation >450 ms or other factors that increase the risk for QT interval prolongation (e.g., heart failure, hypokalemia [defined as serum potassium <3.0 mEq/L that is persistent and refractory to correction], family history of long QT interval syndrome, or concomitant use of medications that may prolong QT interval)
- •16. Any active gastrointestinal or metabolic condition that could interfere with absorption of oral medication
- •17. Active or uncontrolled inflammatory or chronic functional bowel disorder such as Crohn’s Disease, inflammatory bowel disease, chronic diarrhea, or constipation
- •18. Other malignancy within the last 3 years, other than curatively treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, organ-confined or treated nonmetastatic prostate cancer with negative prostate-specific antigen, in situ breast carcinoma after
- •complete surgical resection, or superficial transitional cell bladder carcinoma
- •19. Uncontrolled intercurrent illness, including, but not limited to, ongoing active infection or psychiatric illness or social situation that, in the judgment of the treating physician, would limit compliance with study requirements
- •20. Known seropositivity for human immunodeficiency virus
- •21. Known active hepatitis A, B, or C virus infection
- •22. Women who are pregnant or lactating
- •23. Concurrent enrollment in another interventional trial
研究者
相似试验
进行中（未招募）
1 期
A Phase 2 Dose-Finding Study of Pacritinib in Myelofibrosis PatientsPrimary Myelofibrosis, Post-essential thrombocythemia myelofibrosis,Post polycythaemia vera myelofibrosisMedDRA version: 20.0Level: PTClassification code 10028537Term: MyelofibrosisSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: LLTClassification code 10074691Term: Post polycythaemia vera myelofibrosisSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: LLTClassification code 10074692Term: Post essential thrombocythaemia myelofibrosisSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: SOCClassification code 10029104Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps)System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-001772-28-ITCTI BIOPHARMA CORP.165
进行中（未招募）
1 期
A Phase 2 Dose-Finding Study of Pacritinib in Myelofibrosis PatientsPrimary Myelofibrosis, Post-essential thrombocythemia myelofibrosis, Post polycythaemia vera myelofibrosisMedDRA version: 20.0Level: PTClassification code 10077161Term: Primary myelofibrosisSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10074692Term: Post essential thrombocythaemia myelofibrosisSystem Organ Class: 100000012930MedDRA version: 20.0Level: LLTClassification code 10074691Term: Post polycythaemia vera myelofibrosisSystem Organ Class: 100000012930MedDRA version: 20.0Level: PTClassification code 10028537Term: MyelofibrosisSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-001772-28-FRCTI BioPharma Corp.105
进行中（未招募）
1 期
A Phase 2 Dose-Finding Study of Pacritinib in Myelofibrosis PatientsPrimary Myelofibrosis, Post-essential thrombocythemia myelofibrosis, Post polycythaemia vera myelofibrosisMedDRA version: 20.0Level: PTClassification code 10077161Term: Primary myelofibrosisSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10074692Term: Post essential thrombocythaemia myelofibrosisSystem Organ Class: 100000012930MedDRA version: 20.0Level: LLTClassification code 10074691Term: Post polycythaemia vera myelofibrosisSystem Organ Class: 100000012930MedDRA version: 20.0Level: PTClassification code 10028537Term: MyelofibrosisSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-001772-28-ESCTI BioPharma Corp.165
进行中（未招募）
1 期
A Phase 2 Dose-Finding Study of Pacritinib in Myelofibrosis PatientsPrimary Myelofibrosis, Post-essential thrombocythemia myelofibrosis, Post polycythaemia vera myelofibrosisMedDRA version: 20.0 Level: PT Classification code 10077161 Term: Primary myelofibrosis System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: LLT Classification code 10074692 Term: Post essential thrombocythaemia myelofibrosis System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: LLT Classification code 10074691 Term: Post polycythaemia vera myelofibrosis System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: PT Classification code 10028537 Term: Myelofibrosis System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-001772-28-HUCTI BioPharma Corp.150
已完成
2 期
A Randomized, Open-Label, Dose Finding, Phase 2 Study to Assess the Pharmacodynamics and Safety of the anti-FGF23 antibody, KRN23, in Pediatric Patients with X-linked Hypophosphatemia (XLH)Inheritable from or rickets10027424NL-OMON45206ltragenyx Pharmaceuticals Inc.8